Better care begins with a clearer tracer. Now one of the mainstays of cardiac imaging, PET offers undeniably better imaging and diagnostic potential. When paired with N-13 Ammonia, the value of PET grows exponentially.
We’ve created a first-of-its-kind model that eliminates the expense and effort of launching a cardiac PET program while helping you establish a brand-differentiating service that keeps patients close and drives referrals.
With mounting evidence suggesting COVID-19 has a significant impact on the cardiovascular system, now is the time to get serious about cardiac PET.
Deemed the safest screening option during COVID by ASNC and ASNMII1, rapid pharmacologic cardiac PET is a must-have for your practice.
In addition to reducing exposure-risk for patients and providers, cardiac PET also allows for timely assessment of cardiac conditions.
November: IONETIX in Jenkintown, PA
December: IONETIX in Pittsburgh, PA
January: IONETIX in El Paso, TX
IONETIX AT JENKINTOWN, PA
IONETIX SPOTLIGHT SERIES: WEBINAR
Tuesday, December 15 at 1pm ET
Value of Cardiac PET During COVID-19, Combining MPI and Flow Quantitation
A joint program of SNMMI regional chapters (Greater New York, Pittsburgh, New England and Southwest)
Sponsored and hosted by IONETIX
Munir Ghesani, MD, FACM, FACR
System Chief of Nuclear Medicine, Mount Sinai Health; Associate Professor of Radiology, Icahn School of Medicine, Mount Sinai; Vice-President-Elect, SNMMI
Wednesday, January 13, 2021 at 7pm ET
Sharmila Dorbala, MD, MPH , Associate Professor, Harvard Medical School; Brigham and Women’s Hospital Department of Radiology
Sharmila Dorbala, MD, MPH
Wednesday, March 17, 2021 at 7pm ET